Nothing Special   »   [go: up one dir, main page]

ATE445606T1 - Thrombopoietin-mimetika - Google Patents

Thrombopoietin-mimetika

Info

Publication number
ATE445606T1
ATE445606T1 AT07112106T AT07112106T ATE445606T1 AT E445606 T1 ATE445606 T1 AT E445606T1 AT 07112106 T AT07112106 T AT 07112106T AT 07112106 T AT07112106 T AT 07112106T AT E445606 T1 ATE445606 T1 AT E445606T1
Authority
AT
Austria
Prior art keywords
thrombopoietin mimetics
thrombopoietin
mimetics
Prior art date
Application number
AT07112106T
Other languages
English (en)
Inventor
Kevin Duffy
Daniel Eppley
Connie Erickson-Miller
Julian Jenkins
Nannan Liu
Juan Luengo
Alan Price
Antony Shaw
Sophie Visonneau
Kenneth Wiggall
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26901947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE445606(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE445606T1 publication Critical patent/ATE445606T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C07D231/48—Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hard Magnetic Materials (AREA)
  • Information Transfer Systems (AREA)
  • Vehicle Body Suspensions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT07112106T 2000-05-25 2001-05-24 Thrombopoietin-mimetika ATE445606T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20708400P 2000-05-25 2000-05-25
US22892900P 2000-08-30 2000-08-30

Publications (1)

Publication Number Publication Date
ATE445606T1 true ATE445606T1 (de) 2009-10-15

Family

ID=26901947

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01941599T ATE374772T1 (de) 2000-05-25 2001-05-24 Thrombopoietin-mimetika
AT07112106T ATE445606T1 (de) 2000-05-25 2001-05-24 Thrombopoietin-mimetika

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01941599T ATE374772T1 (de) 2000-05-25 2001-05-24 Thrombopoietin-mimetika

Country Status (30)

Country Link
US (9) US7160870B2 (de)
EP (3) EP1294378B1 (de)
JP (2) JP3813875B2 (de)
KR (2) KR100798568B1 (de)
CN (4) CN101343250B (de)
AR (2) AR030696A1 (de)
AT (2) ATE374772T1 (de)
AU (2) AU7493801A (de)
BE (1) BE2010C018I2 (de)
BR (1) BRPI0111116B8 (de)
CA (1) CA2411468C (de)
CY (4) CY2010012I2 (de)
CZ (1) CZ303176B6 (de)
DE (4) DE60139354D1 (de)
DK (3) DK1864981T3 (de)
ES (3) ES2294000T3 (de)
FR (1) FR10C0034I2 (de)
HK (4) HK1113057A1 (de)
HU (3) HU230487B1 (de)
IL (5) IL152988A0 (de)
LU (1) LU91681I2 (de)
MX (1) MXPA02011621A (de)
MY (1) MY136707A (de)
NO (3) NO324246B1 (de)
NZ (2) NZ522474A (de)
PL (2) PL218617B1 (de)
PT (3) PT1889838E (de)
SI (3) SI1294378T1 (de)
TW (1) TWI305207B (de)
WO (1) WO2001089457A2 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066553A2 (en) 2000-03-08 2001-09-13 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
US20110212054A1 (en) * 2000-05-25 2011-09-01 Glaxosmithkline Llc. Thrombopoietin mimetics
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
EP1370252A4 (de) * 2001-03-01 2006-04-05 Smithkline Beecham Corp Thrombopoietin-mimetika
US7659409B2 (en) 2002-03-19 2010-02-09 Mitsubishi Chemical Corporation 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same
MY142390A (en) 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2003103686A1 (en) * 2002-06-06 2003-12-18 Smithkline Beecham Corporation Thrombopoietin mimetics
CA2495184A1 (en) 2002-08-14 2004-02-26 Nissan Chemical Industries, Ltd. Thrombopoietin receptor activators and process for their production
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
EP1622609A4 (de) * 2003-04-29 2008-09-03 Smithkline Beecham Corp Verfahren zur behandlung von degenerativen erkrankungen/verletzungen
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries
US20090143453A1 (en) * 2003-04-29 2009-06-04 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20100004302A1 (en) * 2003-04-29 2010-01-07 Connie Erickson-Miller Methods for Treating Degenerative Diseases/Injuries
US20090048318A1 (en) * 2003-04-29 2009-02-19 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US7753958B2 (en) * 2003-08-05 2010-07-13 Gordon Charles R Expandable intervertebral implant
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200526638A (en) * 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
CA2581454A1 (en) * 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
MX2007004765A (es) 2004-10-25 2007-07-09 Ligand Pharm Inc Compuestos y metodos que modulan la actividad de la trombopoyetina.
US8552031B2 (en) 2004-12-08 2013-10-08 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
CA2590204C (en) 2004-12-14 2012-12-04 Nissan Chemical Industries, Ltd. Amide compounds and thrombopoietin receptor activators
TW200716580A (en) 2005-06-08 2007-05-01 Smithkline Beecham Corp (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one
WO2007010954A1 (en) 2005-07-15 2007-01-25 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
TWI330184B (en) 2005-07-20 2010-09-11 Nissan Chemical Ind Ltd Pyrazole compounds and thrombopoietin receptor activators
EP1942906A2 (de) * 2005-10-13 2008-07-16 SmithKline Beecham Corporation Verfahren zur konservierung der thrombozyten-wirkung bei lagerung
WO2007052808A1 (ja) 2005-11-07 2007-05-10 Nissan Chemical Industries, Ltd. ヒドラジド化合物及びトロンボポエチンレセプター活性化剤
EP2025671A4 (de) 2006-06-07 2011-04-06 Nissan Chemical Ind Ltd Stickstoffhaltige heterocyclische verbindung und thrombopoietinrezeptoraktivator
CA2670345A1 (en) 2006-12-01 2008-06-12 Stategics, Inc. Thrombopoietin mimetics
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20110129550A1 (en) 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
US20100160644A1 (en) * 2007-04-24 2010-06-24 Jerome Francis Hayes Novel processes of making hydroxy-1-azo-derivatives as tpo mimetics
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
WO2009048953A1 (en) 2007-10-09 2009-04-16 The Trustees Of The University Of Pennsylvania Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en) 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009151862A1 (en) * 2008-05-15 2009-12-17 Smithkline Beecham Corporation Method of treatment
WO2010045310A1 (en) * 2008-10-16 2010-04-22 Glaxosmithkline Llc Method of treating thrombocytopenia
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
EA022756B1 (ru) 2009-04-01 2016-02-29 Плива Хрватска Д.О.О. Кристаллические формы элтромбопага и их применение
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US8476249B2 (en) 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
JP2012526137A (ja) * 2009-05-07 2012-10-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 血小板減少症を治療する方法
US8680150B2 (en) * 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
EP2434894B1 (de) * 2009-05-29 2016-08-31 Novartis AG Verfahren zur verabreichung von thrombopoietinagonisten
CN101921232A (zh) 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
MX2012006281A (es) 2009-12-01 2012-06-28 Basf Se Sistema de resina de extrusion por estirado basada en poliuretano.
CN101805291A (zh) * 2010-04-26 2010-08-18 西北大学 1-(4-异丙苯基)-3-甲基-5-吡唑啉酮及其制备方法和应用
KR20130101519A (ko) 2010-09-01 2013-09-13 노파르티스 아게 Ｈｄａｃ 억제제와 혈소판감소증 약물의 조합물
WO2012102937A2 (en) 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
WO2012121957A1 (en) * 2011-03-08 2012-09-13 Glaxosmithkline Llc Combination
WO2012121958A2 (en) * 2011-03-08 2012-09-13 Glaxosmithkline Llc Combination
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
US20140205582A1 (en) * 2011-07-06 2014-07-24 Cellerant Therapeutics, Inc. Megakaryocyte progenitor cells for production of platelets
AU2012302144B2 (en) * 2011-08-30 2017-06-15 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013072921A2 (en) 2011-09-13 2013-05-23 Glenmark Generics Limited Process for preparation of substituted 3'-hydrazino-biphenyl-3-carboxylic acid compounds
WO2013049605A1 (en) 2011-09-28 2013-04-04 Assia Chemical Industries Ltd. Processes for the preparation of an intermediate in the synthesis of eltrombopag
AU2012322660B2 (en) 2011-10-11 2017-07-06 Dana Farber Cancer Institute, Inc. Pyrazol-3-ones that activate pro-apoptotic BAX
CN104039761A (zh) 2011-11-14 2014-09-10 利亘制药公司 与粒细胞集落刺激因子受体相关的方法和组合物
CA2858069C (en) 2011-12-08 2020-02-11 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
DK2807165T3 (da) 2012-01-27 2019-07-15 Univ Montreal Pyrimido[4,5-b]indol-derivater og anvendelse deraf i ekspansionen af hæmatopoietiske stamceller
CN103360317B (zh) * 2012-04-11 2016-12-14 齐鲁制药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及用途
JP2015154715A (ja) * 2012-05-22 2015-08-27 国立大学法人旭川医科大学 ヒト単核球由来の新規血管再生細胞群及びその分化誘導法
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
US9962370B2 (en) 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
EP2799425A1 (de) 2013-04-29 2014-11-05 Esteve Química, S.A. Herstellungsverfahren eines Agonisten des Thrombopoietinrezeptors
EP3041511B1 (de) 2013-09-02 2021-06-02 Hetero Research Foundation Zusammensetzungen aus eltrombopag
ITMI20131782A1 (it) * 2013-10-25 2015-04-26 Dipharma Francis Srl Procedimento per la preparazione di un agonista della trombopoietina
CN104628647A (zh) * 2013-11-12 2015-05-20 上海医药工业研究院 3-甲基-1-(3,4-二甲基苯基)-2-吡唑啉-5-酮的制备方法
CN104725318A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种爱曲伯帕的合成方法
WO2015111085A2 (en) 2014-01-27 2015-07-30 Cadila Healthcare Limited Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
CN103819406B (zh) * 2014-03-17 2015-04-08 苏州明锐医药科技有限公司 艾曲波帕的制备方法
CA2946446C (en) 2014-04-22 2020-11-03 Universite De Montreal Pyrido-pyrrolo-pyrimidine and pyrido-indole compounds, pharmaceutical compositions containing same and their use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
CN105085287A (zh) * 2014-05-12 2015-11-25 上海医药工业研究院 3`-氨基-2`-羟基-[1,1`-联苯]-3-羧酸的制备方法
CN105085276A (zh) * 2014-05-12 2015-11-25 上海医药工业研究院 艾曲波帕中间体及其制备方法和应用
BR112017000922A2 (pt) 2014-07-17 2018-01-16 Chdi Foundation, Inc. métodos e composições para tratar distúrbios relacionados ao hiv
EP3188737A4 (de) 2014-09-05 2018-05-02 Hetero Research Foundation Kristalline form von eltrombopag-freier säure
WO2016055935A1 (en) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
CA2966150A1 (en) 2014-10-31 2016-05-06 Nissan Chemical Industries, Ltd. Ligand-binding fiber and cell culture substrate using said fiber
CN104829593B (zh) * 2015-03-26 2017-08-25 苏州福来兹检测科技有限公司 一种用于检测溶液中金属离子含量的有机化合物及其应用
WO2017042839A1 (en) 2015-09-08 2017-03-16 Actavis Group Ptc Ehf. Novel eltrombopag salt and preparation thereof
JP2019515070A (ja) 2016-04-21 2019-06-06 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ポリウレタンをベースとする引抜成形製品の製造方法
AU2017289071B2 (en) 2016-06-27 2019-11-21 The General Hospital Corp Dba Massachusetts General Hospital Stimulating platelet generation by activating mitochondrial biogenesis
EP3592793A1 (de) 2017-03-09 2020-01-15 Basf Se Polyurethanformulierungen zur herstellung von verbundelementen
CN107021928B (zh) * 2017-04-01 2022-11-18 常州制药厂有限公司 艾曲波帕新的中间体及其制备方法和应用
EP3395331B1 (de) 2017-04-26 2019-08-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmazeutische tablettenzusammensetzung umfassend eltrombopagolamin
US11072586B2 (en) 2017-10-06 2021-07-27 Assia Chemical Industries Ltd. Solid state forms of eltrombopag choline
EP3409272B1 (de) 2018-03-07 2020-06-24 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmazeutische zusammensetzung mit eltrombopag olamin, reduzierendem zucker und polymerem bindemittel
CN110467531B (zh) * 2018-05-09 2022-04-19 新发药业有限公司 一种3’-硝基-2’-羟基联苯-3-甲酸的制备方法
US11161821B2 (en) * 2018-06-01 2021-11-02 Aurobindo Pharma Ltd. Process for the preparation of Eltrombopag olamine and its intermediates
EP3604285B1 (de) 2018-08-02 2020-06-17 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Hochstabile kristalline form d1 des eltrombopag-monoethanolamin-salzes
EP3604284B1 (de) 2018-08-02 2020-11-11 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Kristalline form d des eltrombopag-monoethanolamin-salzes
EP3909645A4 (de) * 2019-01-08 2022-07-27 Jiangsu Hengrui Medicine Co., Ltd. Dosierungsschema für ein bicyclisches substituiertes pyrazolonazolderivat
CN114072386A (zh) 2019-07-04 2022-02-18 F.I.S.-菲博利佳意大利合成面料股份公司 制备用于合成艾曲波帕或其盐的关键中间体的改进方法
JP7083793B2 (ja) * 2019-09-10 2022-06-13 Ｊｆｅケミカル株式会社 パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法
US20210169854A1 (en) 2019-09-20 2021-06-10 Novartis Ag 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
WO2021078077A1 (zh) * 2019-10-21 2021-04-29 广东东阳光药业有限公司 乙酰化艾曲波帕的新晶型及其制备方法
WO2021078076A1 (zh) * 2019-10-21 2021-04-29 广东东阳光药业有限公司 乙酰化艾曲波帕的新晶型及其制备方法
EP4069204A1 (de) 2019-12-06 2022-10-12 Synthon B.V. Pharmazeutische zusammensetzung mit eltrombopag-bis(monoethanolamin)
WO2021110942A1 (en) 2019-12-06 2021-06-10 Synthon B.V. Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
TR202014694A1 (tr) 2020-09-16 2022-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Eltrombopag olami̇n i̇çeren bi̇r kati oral farmasöri̇k formülasyon
WO2022201087A1 (en) 2021-03-25 2022-09-29 Novartis Ag 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
CN113336704B (zh) * 2021-06-11 2022-10-11 上海大学 丹参素衍生物及其制备方法和医药用途
CN114507186A (zh) * 2021-12-02 2022-05-17 天津力生制药股份有限公司 一种艾曲波帕的制备方法
WO2023111187A1 (en) 2021-12-15 2023-06-22 Galenicum Health, S.L.U Pharmaceutical compositions comprising eltrombopag

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE193350C (de)
US851444A (en) 1905-11-13 1907-04-23 Agfa Ag Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en) 1953-02-27 1957-07-24 Ciba Ltd Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
US2809963A (en) * 1954-10-26 1957-10-15 Ciba Ltd Azo-dyestuffs
DE1046220B (de) * 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
GB826207A (en) 1956-07-23 1959-12-31 Bayer Ag ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en) 1956-11-20 1960-08-23 Agfa Ag Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en) 1965-04-09 1968-01-30 Interchem Corp Disazo pyrazolone pigments
US4435417A (en) 1981-02-20 1984-03-06 Gruppo Lepetit S.P.A. Antiinflammatory 3H-naphtho[1,2-d]imidazoles
ES523609A0 (es) 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
FR2559483B1 (fr) * 1984-02-10 1986-12-05 Sandoz Sa Composes heterocycliques contenant des groupes basiques et/ou cationiques, leur preparation et leur utilisation comme colorants
FI91869C (fi) 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4880788A (en) 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (de) 1993-08-13 1995-02-15 Ciba-Geigy Ag Pigmentsalze
DE69423661T2 (de) 1993-12-28 2000-11-23 Dai Nippon Printing Co., Ltd. Thermische Übertragungsaufzeichnungsschicht, die einen bestimmten Farbstoff verwendet
GB2285446B (en) * 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
CZ221496A3 (en) 1994-02-14 1997-07-16 Zymogenetics Inc Haematopoetic protein, materials and processes for preparing thereof
US5482546A (en) 1994-03-30 1996-01-09 Canon Kabushiki Kaisha Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US5760038A (en) 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en) 1995-02-13 1998-05-05 Engelhard Corporation Pigment compositions
IL122102A (en) 1995-06-07 2002-07-25 Glaxo Group Ltd Peptides and compounds bound to the thrombopoietin receptor, pharmaceutical preparations containing them and their use as medicinal substances
US5622818A (en) * 1995-11-29 1997-04-22 Eastman Kodak Company Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en) 1996-05-30 1997-09-23 Engelhard Corporation Pigment compositions
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
GB9715830D0 (en) 1997-07-25 1997-10-01 Basf Ag Reactive dyes containing piperazine
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
ES2284217T3 (es) 1997-10-31 2007-11-01 Smithkline Beecham Corporation Complejos metalicos novedosos.
DE19851389A1 (de) 1998-11-07 2000-05-11 Dystar Textilfarben Gmbh & Co Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en) * 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
US6750342B1 (en) * 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US7026334B1 (en) 1999-07-26 2006-04-11 Shionogi & Co., Ltd. Thiazolidine compounds and pharmaceutical compositions exhibiting thrombopoietin receptor agonism
JP4488663B2 (ja) * 1999-09-10 2010-06-23 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー トロンボポイエチン模倣物
EP1223944B1 (de) * 1999-09-24 2007-01-03 SmithKline Beecham Corporation Thrombopoietinmimetika
JP2003513965A (ja) 1999-11-05 2003-04-15 スミスクライン・ビーチャム・コーポレイション セミカルバゾン誘導体およびそれらのトロンボポエチン模倣物としての使用
ES2160560T1 (es) 1999-11-10 2001-11-16 Curacyte Ag Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias.
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
AR030273A1 (es) * 2000-03-10 2003-08-20 Smithkline Beecham Corp Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina
US6214813B1 (en) 2000-04-07 2001-04-10 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
US6436915B1 (en) 2000-04-07 2002-08-20 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US6642265B1 (en) * 2000-09-08 2003-11-04 Smithkline Beecham Corporation Thrombopoietin mimetics
JP2004520302A (ja) 2000-12-19 2004-07-08 スミスクライン・ビーチャム・コーポレイション トロンボポエチン模倣物
CA2432800A1 (en) 2000-12-21 2002-07-25 Smithkline Beecham Corporation Regulated activation of cell-membrane receptors by metal-chelating agonists
US20040063764A1 (en) 2001-01-26 2004-04-01 Hiroshi Takemoto Halogen compounds having thrombopoietin receptor agonism
EP1361220A4 (de) 2001-01-26 2005-09-07 Shionogi & Co Cyclische verbindungen mit thrombopoietinrezeporagonismus
EP1370252A4 (de) 2001-03-01 2006-04-05 Smithkline Beecham Corp Thrombopoietin-mimetika
JP3927001B2 (ja) 2001-06-15 2007-06-06 三菱化学株式会社 色素セット、インクセット並びに記録方法
US6560161B1 (en) * 2001-08-30 2003-05-06 Micron Technology, Inc. Synchronous flash memory command sequence
MXPA04005204A (es) 2001-11-30 2005-11-04 Quadra Logic Tech Inc Derivados de hidrazonipirazol y su uso como terpapeuticos.
WO2003074550A2 (en) 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
MY142390A (en) 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2003103686A1 (en) 2002-06-06 2003-12-18 Smithkline Beecham Corporation Thrombopoietin mimetics
TWI324593B (en) * 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
JP2006514951A (ja) 2002-12-13 2006-05-18 スミスクライン・ビーチャム・コーポレイション トロンボポエチン模倣物
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries
EP1622609A4 (de) * 2003-04-29 2008-09-03 Smithkline Beecham Corp Verfahren zur behandlung von degenerativen erkrankungen/verletzungen
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
MX2007004765A (es) * 2004-10-25 2007-07-09 Ligand Pharm Inc Compuestos y metodos que modulan la actividad de la trombopoyetina.
EP1942906A2 (de) * 2005-10-13 2008-07-16 SmithKline Beecham Corporation Verfahren zur konservierung der thrombozyten-wirkung bei lagerung
CA2670345A1 (en) * 2006-12-01 2008-06-12 Stategics, Inc. Thrombopoietin mimetics

Also Published As

Publication number Publication date
DK1889838T3 (da) 2010-02-08
US20070129338A1 (en) 2007-06-07
CY1107087T1 (el) 2012-01-25
KR20030060773A (ko) 2003-07-16
IL152988A0 (en) 2003-06-24
DE122010000037I1 (de) 2011-01-27
FR10C0034I1 (de) 2010-06-08
CN101343250B (zh) 2011-09-21
NO324246B1 (no) 2007-09-17
FR10C0034I2 (fr) 2011-04-29
CY2010012I1 (el) 2012-01-25
HUP0302257A3 (en) 2007-03-28
HUP0800710A2 (hu) 2003-10-28
HK1117825A1 (en) 2009-01-23
NZ522474A (en) 2004-10-29
PL216528B1 (pl) 2014-04-30
JP3813875B2 (ja) 2006-08-23
HK1113057A1 (en) 2008-09-19
AU2001274938C1 (en) 2006-09-28
DE60130760D1 (de) 2007-11-15
US7439342B2 (en) 2008-10-21
PT1294378E (pt) 2008-01-09
CN101343251A (zh) 2009-01-14
DE60140224D1 (de) 2009-11-26
HUP0302257A2 (hu) 2003-10-28
HU0800310D0 (en) 2008-07-28
JP2003534257A (ja) 2003-11-18
IL193617A0 (en) 2009-02-11
CY1109435T1 (el) 2014-08-13
PL218617B1 (pl) 2015-01-30
PL359270A1 (en) 2004-08-23
HU227476B1 (en) 2011-07-28
US7473686B2 (en) 2009-01-06
US7674887B2 (en) 2010-03-09
CN1444477A (zh) 2003-09-24
CZ303176B6 (cs) 2012-05-16
HU230387B1 (hu) 2016-03-29
JP2006137764A (ja) 2006-06-01
CY1109730T1 (el) 2014-09-10
US20090176973A1 (en) 2009-07-09
US7790704B2 (en) 2010-09-07
EP1889838B1 (de) 2009-10-14
EP1294378A2 (de) 2003-03-26
IL193619A0 (en) 2009-02-11
ATE374772T1 (de) 2007-10-15
ES2294000T3 (es) 2008-04-01
ES2328179T3 (es) 2009-11-10
HK1056114A1 (zh) 2004-02-06
NO2010017I2 (no) 2012-06-11
IL193618A0 (en) 2009-02-11
CZ20023852A3 (cs) 2003-05-14
US7332481B2 (en) 2008-02-19
CN101342169A (zh) 2009-01-14
CA2411468C (en) 2008-04-15
US20090176746A1 (en) 2009-07-09
CY2010012I2 (el) 2020-05-29
LU91681I2 (fr) 2010-06-21
EP1864981A1 (de) 2007-12-12
TWI305207B (en) 2009-01-11
CA2411468A1 (en) 2001-11-29
EP1294378A4 (de) 2004-01-28
DE60139354D1 (de) 2009-09-03
EP1864981B1 (de) 2009-07-22
PT1864981E (pt) 2009-08-31
MY136707A (en) 2008-11-28
DK1864981T3 (da) 2009-09-07
JP4546919B2 (ja) 2010-09-22
NO2020040I1 (no) 2020-11-19
WO2001089457A3 (en) 2002-03-07
EP1294378B1 (de) 2007-10-03
IL152988A (en) 2009-02-11
HU230487B1 (hu) 2016-08-29
CN100423721C (zh) 2008-10-08
CN101343250A (zh) 2009-01-14
US20080214640A1 (en) 2008-09-04
SI1864981T1 (sl) 2009-12-31
EP1864981B8 (de) 2009-11-11
KR100798568B1 (ko) 2008-01-28
BE2010C018I2 (de) 2020-08-20
EP1889838A1 (de) 2008-02-20
US20080090996A1 (en) 2008-04-17
SI1294378T1 (sl) 2008-02-29
NO20025566D0 (no) 2002-11-20
LU91681I9 (de) 2019-01-03
DK1294378T3 (da) 2008-01-28
CN101343251B (zh) 2011-11-09
MXPA02011621A (es) 2004-05-17
AU7493801A (en) 2001-12-03
US7160870B2 (en) 2007-01-09
US20070179192A1 (en) 2007-08-02
BR0111116A (pt) 2003-04-08
AR066036A2 (es) 2009-07-22
AU2001274938B2 (en) 2006-01-19
US7452874B2 (en) 2008-11-18
US20040019190A1 (en) 2004-01-29
KR20070087255A (ko) 2007-08-27
US20090155203A1 (en) 2009-06-18
AR030696A1 (es) 2003-09-03
US20080090787A1 (en) 2008-04-17
HK1055561A1 (en) 2004-01-16
ES2334843T3 (es) 2010-03-16
KR100847172B1 (ko) 2008-07-17
NO20025566L (no) 2003-01-22
IL193617A (en) 2013-06-27
NZ533308A (en) 2005-10-28
HU0800710D0 (en) 2009-01-28
WO2001089457A2 (en) 2001-11-29
SI1889838T1 (sl) 2010-02-26
PT1889838E (pt) 2010-01-19
US7335649B2 (en) 2008-02-26
PL393259A1 (pl) 2011-07-04
DE60130760T2 (de) 2008-07-17
NO2010017I1 (no) 2010-09-20
US7648971B2 (en) 2010-01-19
BR0111116B1 (pt) 2013-10-08
BRPI0111116B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
ATE374772T1 (de) Thrombopoietin-mimetika
DZ3409A1 (fr) Association therapeuthique
DE50105915D1 (de) Schutzhülle
EP1349613A4 (de) Thrombopoietinmimetika
DE60113450D1 (de) Antimikrobielle chinolone
ATA2932001A (de) Schneefräse
ATE291365T1 (de) Bett-schreibtisch-kombinationsmöbel
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
AR027931A1 (es) Antitranspirantes
AR027982A1 (es) Aril- y heteroarilsulfonatos
ATA7092001A (de) Skibindungseinstellgerät
AT500246B8 (de) Chokerring
ATA12252000A (de) Regensinkkasten
ATA21172000A (de) Hackbrett
ATA11602000A (de) Sonnenstandsnachführungssystem
ATA19392000A (de) Kippflügelflugzeug
ATA17542000A (de) Hydraulikzylinder
SE0002352D0 (sv) New combination
SE0001188D0 (sv) New combination
SE0002606D0 (sv) Watcher
AR028386A1 (es) 1-aroil-piperidinil benzamidinas
ATA18812000A (de) Bodenplatte
ATA11632001A (de) Fräsbrecherfahrzeug

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 1889838

Country of ref document: EP